ArticleJournal of immunology (Baltimore, Md. : 1950)2008
Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha/beta.
Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 73 citations in OpenAlex.
- Type I interferon restricts mRNA vaccine efficacy through suppression of antigen uptake in cDCs.NPJ vaccines · 2026Article
- Synthetic double-stranded RNA in antiviral immunity and vaccine adjuvant: insights into poly(I:C) and poly(A:U).Frontiers in immunology · 2026Review
- Review
- Size Tuning of Mesoporous Silica Adjuvant for One-Shot Vaccination with Long-Term Anti-Tumor Effect.Pharmaceutics · 2024Article
- Lipid Nanoparticle Encapsulation Empowers Poly(I:C) to Activate Cytoplasmic RLRs and Thereby Increases Its Adjuvanticity.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Ex vivo treatment with poly (I:C) alleviates the exhausted phenotype of tumor-infiltrating TCD8Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Clonal lineage tracing reveals mechanisms skewing CD8+ T cell fate decisions in chronic infection.The Journal of experimental medicine · 2023Article
- Review
- Widespread discrepancy ineLife · 2022Article
- Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.Cancer treatment and research · 2022Article
- Cytokine Storm and Neuropathological Alterations in Patients with Neurological Manifestations of COVID-19.Current Alzheimer research · 2022Article
- Monophosphoryl Lipid A and Poly I:C Combination Adjuvant Promoted Ovalbumin-Specific Cell Mediated Immunity in Mice Model.Biology · 2021Article
- Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants.Frontiers in cellular and infection microbiology · 2021Review
- Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective.International journal of biological macromolecules · 2020Article
- Neurological consequences of COVID-19: what have we learned and where do we go from here?Journal of neuroinflammation · 2020Review
- Comprehensive Analysis of the Safety Profile of a Single-Stranded RNA Nano-Structure Adjuvant.Pharmaceutics · 2019Article
- Peripheral viral challenge exacerbates experimental autoimmune encephalomyelitis.Metabolic brain disease · 2019Article
- Article
- The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector.BMC immunology · 2018Article
- Responses to LPS boost effector CD8 T-cell accumulation outside of signals 1 and 2.Cellular & molecular immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Poly(I:C) is an adjuvant used for antitumor treatment and vaccines because of its prominent effects on CD8 T cells and NK cells. Poly(I:C) binds TLR3 and this interaction is thought to be central for driving cell-mediated immune responses. We investigated the importance of TLR3 in poly(I:C)-mediated endogenous CD8 T cell responses using the pathogenic T cell stimulant Staphylococcus aureus enterotoxin A. While the responsive CD8 T cells expanded comparably in both wild-type and TLR3(-/-) mice, differentiation of effector CD8 T cells was enhanced by poly(I:C) in the TLR3(-/-) mice. A higher percentage of Ag-specific CD8 T cells became IFN-gamma and TNF-alpha producers in the absence of TLR3 signaling. Consistent with this boosted response was the observation that TLR3-deficient cells synthesized less IL-10 compared with TLR3-sufficient cells in response to poly(I:C). Ultimately, however, the fundamental mechanism of CD8 effector T cell differentiation through the TLR3-independent pathway was shown to be completely IFN-alpha/beta-dependent. Administration of IFN-alpha/beta-neutralizing Abs abolished the poly(I:C) effects in TLR3(-/-) mice. These findings reveal specific roles of how dsRNA receptors shape CD8 T cell responses, which should be considered as poly(I:C) is authenticated as a therapeutic adjuvant used in vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.